Home › Phases › Preclinical

Preclinical (145 companies)

Companies with at least one active program at Preclinical.

Ticker Company Therapeutic areas Preclinical programs Lead stage Mkt cap Programs
FDMT 4D Molecular Therapeutics OphthalmologyRespiratory Rare 2 Phase 3 $608M 5
AARD Aardvark Therapeutics DermatologyMetabolic+1 Rare 1 Phase 3 $25.2M 3
ABSI Absci DermatologyGI/Hepatology+1 3 Phase 1 $1.31B 6
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 1 Phase 2 $536M 7
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 2 Phase 2 $61.4M 9
ACTU Actuate Therapeutics Oncology 1 Phase 2 $15.2M 4
ABOS Acumen Pharmaceuticals Neurology 2 Phase 2 $16.6M 4
ADAG Adagene Oncology 3 Phase 2 $99.4M 10
ADCT ADC Therapeutics Oncology 1 Approved $172M 5
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
ADMA Adma Biologics ImmunologyInfectious Disease Rare 1 Approved $3.02B 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 2 Phase 2 $292M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 2 Approved $111M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 1 NDA Submitted $41.9M 5
ATHE Alterity Therapeutics Neurology Rare 1 Phase 2 $35.7M 2
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.54B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 2 Phase 2 $161M 6
ANIX Anixa Biosciences Oncology 1 Phase 1 $92.8M 3
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 2 Phase 2 — 9
APVO Aptevo Therapeutics Oncology 6 Phase 1 $1.6M 8
RCUS Arcus Biosciences DermatologyImmunology+1 2 Phase 3 $2.36B 8
ARDX Ardelyx GI/HepatologyRenal 1 Approved $799M 4
AVBP ArriVent BioPharma Oncology 2 Phase 3 $553M 7
ARVN Arvinas NeurologyOncology Rare 1 Approved $447M 10
ATAI Atai Beckley Neurology 2 Phase 2 $2.73B 5
AXSM Axsome Therapeutics Neurology Rare 2 Approved $7.15B 15
BLTE Belite Bio MetabolicOphthalmology Rare 4 NDA Submitted $6.35B 6
BCYC Bicycle Therapeutics Oncology 1 Phase 2 $224M 4
BDTX Black Diamond Therapeutics Oncology 1 Phase 2 $82.8M 4
BCTX BriaCell Therapeutics Oncology 6 Phase 3 $30.7M 8
CADL Candel Therapeutics Oncology 1 Phase 3 $424M 4
CRDL Cardiol Therapeutics Cardiovascular Rare 1 Phase 3 $124M 4
CLRB Cellectar Biosciences Oncology 1 Phase 2 $9.2M 7
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 5 Phase 1 $249M 9
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $4.85B 7
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $858M 7
COYA Coya Therapeutics Neurology Rare 4 Phase 2 $70.8M 6
CUE Cue Biopharma ImmunologyOncology 2 Phase 2 $23.7M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 2 NDA Submitted $602M 10
CTMX CytomX Therapeutics Oncology 1 Phase 1 $423M 7
IRON Disc Medicine GI/HepatologyHematology+2 Rare 1 Phase 3 $3.49B 9
DYN Dyne Therapeutics MetabolicNeurology Rare 8 NDA Submitted $3.00B 10
EIKN Eikon Therapeutics Oncology 1 Phase 2 $279M 13
ELTX Elicio Therapeutics Oncology 3 Phase 2 $40.5M 6
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 2 Approved $253M 8
ENTX Entera Bio GI/HepatologyMetabolic Rare 2 Phase 2 $522M 4
ERAS Erasca Oncology 1 Phase 1 $4.87B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.84B 17
EVMN Evommune DermatologyImmunology+1 2 Phase 2 $290M 6
EXEL Exelixis CardiovascularOncology 3 Approved $16.7B 23
EYPT EyePoint Ophthalmology 1 Phase 3 $34.1M 2
FATE Fate Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $124M 10
FHTX Foghorn Therapeutics Oncology 3 Preclinical $110M 4
FBIO Fortress Biotech DermatologyHematology+4 Rare 3 Approved $61.4M 16
GANX Gain Therapeutics MetabolicNeurology Rare 4 Phase 1 $52.5M 5
HRMY Harmony Biosciences MetabolicNeurology Rare 6 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 2 Approved $1.11B 15
IDYA IDEAYA Biosciences Oncology 1 NDA Submitted $2.65B 15
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $116M 4
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.44B 12
IMNM Immunome Oncology Rare 2 NDA Submitted $2.03B 9
INAB IN8bio ImmunologyOncology 1 Phase 1 $8.9M 4
INBX Inhibrx Biosciences Oncology 1 NDA Submitted $1.10B 6
IVVD Invivyd Infectious Disease 2 Approved $152M 5
JBIO Jade Biosciences ImmunologyRenal Rare 2 Phase 2 $1.07B 4
KAPA Kairos Pharma Oncology 7 Phase 2 $1.9M 12
KZIA Kazia Therapeutics NeurologyOncology Rare 5 Phase 2 $60.7M 13
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $222M 5
KOD Kodiak Sciences Ophthalmology 2 Phase 3 $6.33B 8
KURA Kura Oncology MetabolicOncology 4 Approved $688M 13
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 1 Phase 2 $10.4B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 7 Phase 2 $236M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 10 Phase 2 $207M 13
LGVN Longeveron CardiovascularNeurology Rare 1 Phase 2 $7.1M 3
MAIA MAIA Biotechnology Oncology 6 Phase 3 $77.2M 8
MRKR Marker Therapeutics Oncology 1 Phase 1 $14.0M 5
MBX MBX Biosciences Metabolic Rare 2 Phase 3 $2.64B 4
MDNAF Medicenna Therapeutics Oncology 7 Phase 2 $14.8M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 7 Phase 3 $827M 16
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 3 Phase 2 $47.7M 8
MBRX Moleculin Biotech Oncology 4 Phase 2 $7.3M 9
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 1 Phase 2 $775M 7
NKTR Nektar Therapeutics DermatologyImmunology+2 4 Phase 3 $1.23B 11
NGEN NervGen Pharma Neurology 2 Phase 3 $211M 3
NRSN NeuroSense Therapeutics Neurology Rare 1 Phase 2 $2.9M 3
NRXP NRX Pharmaceuticals Neurology Rare 4 Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
OCGN Ocugen Infectious DiseaseOphthalmology Rare 3 Phase 3 $257M 12
OCS Oculis Holding NeurologyOphthalmology Rare 2 Phase 3 $418M 5
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.04B 6
ONCY Oncolytics Biotech Oncology 1 Phase 2 $51.7M 4
OKUR OnKure Therapeutics Oncology 2 Preclinical $104M 2
IRD Opus Genetics Ophthalmology Rare 5 Approved $391M 12
ORIC Oric Pharmaceuticals Oncology 2 Phase 3 $831M 5
ORKA Oruka Therapeutics DermatologyImmunology Rare 2 Phase 2 $6.53B 7
OVID Ovid Therapeutics Neurology Rare 2 Phase 2 $419M 4
PTN Palatin Technologies ImmunologyMetabolic+1 1 Phase 3 $9.5M 5
PALI Palisade Bio Immunology 1 Phase 2 $181M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 $16.0M 4
CATX Perspective Therapeutics Oncology 1 Phase 1 $104M 5
PHIO Phio Pharmaceuticals Oncology 1 Phase 1 $8.6M 4
PYPD PolyPid Infectious DiseaseMetabolic+1 3 NDA Submitted $138M 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 1 Phase 1 $197M 5
PRME Prime Medicine GI/HepatologyRespiratory Rare 1 Phase 1 $699M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $4.8M 7
PMN ProMIS Neurosciences Neurology Rare 8 Phase 1 $28.9M 9
PRQR ProQR Therapeutics MetabolicNeurology Rare 3 Phase 1 $163M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 5 Approved $8.14B 12
QTTB Q32 Bio Dermatology 2 Phase 2 $258M 3
QNRX Quoin Pharmaceuticals DermatologyImmunology Rare 2 Phase 2 $236M 4
RAPP Rapport Therapeutics Neurology 3 Phase 3 $1.41B 6
RXRX Recursion Pharmaceuticals Oncology 3 Phase 2 $1.69B 6
RLMD Relmada Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $321M 4
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 5 Phase 3 $4.7M 11
RVMD Revolution Medicines Oncology 3 Approved $35.2B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 1 Approved $8.08B 14
SANA Sana Biotechnology MetabolicOncology 3 Phase 1 $563M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 1 Approved $1.58B 11
SCYX Scynexis Infectious DiseaseRenal Rare 1 Approved $28.4M 5
SLS SELLAS Life Sciences Group Oncology 3 Phase 3 $3.90B 9
SEPN Septerna ImmunologyMetabolic+1 Rare 2 Phase 1 $1.90B 5
SLDB Solid Biosciences CardiovascularNeurology Rare 3 Phase 3 $695M 6
SPRB Spruce Biosciences Metabolic Rare 1 Preclinical $116M 2
SYRE Spyre Therapeutics DermatologyImmunology Rare 1 Phase 2 $8.91B 10
GPCR Structure Therapeutics MetabolicRespiratory Rare 1 Phase 3 $3.90B 5
STRO Sutro Biopharma Oncology 1 Phase 1 $148M 3
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 3 Approved $822M 7
TSHA Taysha Gene Therapies Neurology Rare 2 Phase 3 $1.30B 4
TLX Telix Pharmaceuticals Oncology 6 Approved $3.01B 25
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $83.2M 5
TVTX Travere Therapeutics MetabolicRenal Rare 2 Approved $4.91B 7
TTRX Turn Therapeutics DermatologyInfectious Disease Rare 2 Phase 2 $261M 4
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 1 Approved $1.70B 10
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
PCVX Vaxcyte Infectious Disease 2 Phase 3 $9.40B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 1 Approved $1.89B 6
VIR Vir Biotechnology Infectious DiseaseOncology Rare 1 Phase 3 $1.58B 6
VRDN Viridian Therapeutics ImmunologyOphthalmology 3 Approved $3.41B 7
VYGR Voyager Therapeutics MetabolicNeurology Rare 7 Phase 1 $94.6M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 2 Phase 3 $69.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 1 Phase 2 $560M 5
XENE Xenon Pharmaceuticals Neurology Rare 1 NDA Submitted $3.81B 9
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 2 NDA Submitted $1.88B 11
ZYME Zymeworks OncologyRespiratory 3 Approved $1.78B 12